Research Leader for New Cancer Drug to Speak at SMi's Cancer Vaccine Summit
London, UK (PRWEB UK) 13 August 2013 -- According to an article published online by the Telegraph this week, scientists at the University of Southampton have developed a new drug that works by increasing the ability of the immune system to recognise and attack tumours. A £5 million European Union funded trial of the new treatment is due to start next year. http://bit.ly/1bm275Q - 11 August 2013
SMi’s keynote speaker at Cancer Vaccines 2013, Prof Martin Glennie, who has led the research at the University of Southampton, said:
“Some cancers are able to switch the immune cells off. We have been working on a drug that effectively puts the foot on the accelerator to rev up the immune system... If we use this with a vaccine we can steer the immune cells and train them to target the cancer.”
Prof. Martin Glennie will be providing delegates at SMi’s 2nd annual Cancer Vaccines conference with a unique insight on anti-cancer immunity. The presentation titled: Developing Antibodies to Stimulate Anti-Cancer Immunity will:
• Discuss the nature of anti-cancer immunity and the ability of the immune system to recognise most types of cancer.
• Explore how antibodies recognising key members of the TNFR super family can stimulate T-cell responses against cancer.
• Show that these immuno stimulating antibodies need to engage Fc receptors in the host to provide sufficient cross-linking of the various TNFR’s.
• Discuss how antibody engineering will be used to optimise cross-linking activity in vivo.
Cancer Vaccines | 18-19 September 2013, London UK
To meet Prof. Martin Glennie and for further information visit the event homepage at: http://www.canervaccinesevent.com
Sonal Patel, SMi Group Ltd, http://www.smi-online.co.uk/2013militaryairlift10.asp, 0-207-827-6106, [email protected]
Share this article